Auriga Reiterates a 'Buy' on Cerner (CERN); Strong Results, Record Q2 Bookings
Tweet
Share
E-mailGet Alerts CERN Hot Sheet
Price: $94.92 --0%
Rating Summary:
8 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Auriga reiterates a 'Buy' on Cerner (NASDAQ: CERN), raises price target from $65 to $72.
Auriga analyst says, "We are reiterating our rating on Cerner following a strong quarter in which results exceeded top- and bottom-line expectations, and were supported by record bookings for a second quarter ($100 million above the midpoint of guidance). We have noted previously and reiterate that as meaningful use hurdles get tougher, the hospital IT market is becoming a two-horse race, with CERN and privately held Epic leading the field. Specifically, CERN continues to win its fair share of replacement business, is leaps ahead of any competitor internationally, and its foray into medical device integration and more recently, the long-term care market, is gaining traction. As a must-own healthcare IT stock, we are increasing our price target to $72, reiterating our BUY, and recommend becoming aggressive on dips. "
For more ratings news on Cerner click here and for the rating history of Cerner click here.
Shares of Cerner closed at $62.02 yesterday.
Auriga analyst says, "We are reiterating our rating on Cerner following a strong quarter in which results exceeded top- and bottom-line expectations, and were supported by record bookings for a second quarter ($100 million above the midpoint of guidance). We have noted previously and reiterate that as meaningful use hurdles get tougher, the hospital IT market is becoming a two-horse race, with CERN and privately held Epic leading the field. Specifically, CERN continues to win its fair share of replacement business, is leaps ahead of any competitor internationally, and its foray into medical device integration and more recently, the long-term care market, is gaining traction. As a must-own healthcare IT stock, we are increasing our price target to $72, reiterating our BUY, and recommend becoming aggressive on dips. "
For more ratings news on Cerner click here and for the rating history of Cerner click here.
Shares of Cerner closed at $62.02 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
- Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
